Skip to Content
Merck
  • Cancer cells differentially activate and thrive on de novo lipid synthesis pathways in a low-lipid environment.

Cancer cells differentially activate and thrive on de novo lipid synthesis pathways in a low-lipid environment.

PloS one (2014-09-13)
Veerle W Daniëls, Karine Smans, Ines Royaux, Melanie Chypre, Johannes V Swinnen, Nousheen Zaidi
ABSTRACT

Increased lipogenesis is a hallmark of a wide variety of cancers and is under intense investigation as potential antineoplastic target. Although brisk lipogenesis is observed in the presence of exogenous lipids, evidence is mounting that these lipids may adversely affect the efficacy of inhibitors of lipogenic pathways. Therefore, to fully exploit the therapeutic potential of lipid synthesis inhibitors, a better understanding of the interrelationship between de novo lipid synthesis and exogenous lipids and their respective role in cancer cell proliferation and therapeutic response to lipogenesis inhibitors is of critical importance. Here, we show that the proliferation of various cancer cell lines (PC3M, HepG2, HOP62 and T24) is attenuated when cultured in lipid-reduced conditions in a cell line-dependent manner, with PC3M being the least affected. Interestingly, all cell lines--lipogenic (PC3M, HepG2, HOP62) as well as non-lipogenic (T24)--raised their lipogenic activity in these conditions, albeit to a different degree. Cells that attained the highest lipogenic activity under these conditions were best able to cope with lipid reduction in term of proliferative capacity. Supplementation of the medium with very low density lipoproteins, free fatty acids and cholesterol reversed this activation, indicating that the mere lack of lipids is sufficient to activate de novo lipogenesis in cancer cells. Consequently, cancer cells grown in lipid-reduced conditions became more dependent on de novo lipid synthesis pathways and were more sensitive to inhibitors of lipogenic pathways, like Soraphen A and Simvastatin. Collectively, these data indicate that limitation of access to exogenous lipids, as may occur in intact tumors, activates de novo lipogenesis is cancer cells, helps them to thrive under these conditions and makes them more vulnerable to lipogenesis inhibitors. These observations have important implications for the design of new antineoplastic strategies targeting the cancer cell's lipid metabolism.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
SyntheChol® NS0 Supplement, 500 ×, synthetic cholesterol, animal component-free, aqueous solution, sterile-filtered, suitable for cell culture
Sigma-Aldrich
Trypan Blue, ≥80% (HPLC), Dye content 60 %
Supelco
Cholesterol solution, certified reference material, 10 mg/mL in chloroform
Sigma-Aldrich
Cholesterol, from lanolin, ≥99.0% (GC)
Sigma-Aldrich
Cholesterol, tested according to Ph. Eur.
Sigma-Aldrich
Trypan Blue, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Cholesterol, powder, BioReagent, suitable for cell culture, ≥99%
Sigma-Aldrich
Cholesterol, Sigma Grade, ≥99%
Sigma-Aldrich
Cholesterol, from sheep wool, ≥92.5% (GC), powder
SAFC
Cholesterol, from sheep wool, Controlled origin, meets USP/NF testing specifications
Supelco
Cholesterol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Simvastatin, ≥97% (HPLC), solid
Simvastatin, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Trypan Blue solution, 0.4%, for microscopy
Sigma-Aldrich
Trypan Blue solution, 0.4%, liquid, sterile-filtered, suitable for cell culture
Supelco
Simvastatin, analytical standard
USP
Simvastatin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Glyceryl trilinoleate, ≥98% (TLC), liquid
Sigma-Aldrich
Glyceryl trilinolenate, ≥97% (TLC), liquid
SAFC
Cholesterol, Plant-Derived, SyntheChol®
Supelco
Simvastatin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Glyceryl trilinoleate, analytical standard